Affiliation:
1. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jouf University, Sakaka, Jouf, Saudi Arabia
Abstract
Background:
One of the most prevalent neurodegenerative diseases with increasing age
is Parkinson’s disease (PD). Its pathogenesis is unclear and mainly confined to glutamate toxicity
and oxidative stress. The dyskinesia and motor fluctuations and neuroprotective potential are the
major concerns which are still unmet in PD therapy.
Objective:
This article is a capsulization of the role of MAO-B in the treatment of PD,
pharmacological properties, safety and efficiency, clinical evidence through random trials, future
therapies and challenges.
Conclusion:
: MAO-B inhibitors are well tolerated for the treatment of PD because of their
pharmacokinetic properties and neuroprotective action. Rasagiline and selegiline were
recommended molecules for early PD and proven safe and provide a modest to significant rise in
motor function, delay the use of levodopa and used in early PD. Moreover, safinamide is
antiglutamatergic in action. When added to Levodopa, these molecules significantly reduce the offtime
with a considerable improvement of non-motor symptoms. This review also discusses the new
approaches in therapy like the use of biomarkers, neurorestorative growth factors, gene therapy,
neuroimaging, neural transplantation, and nanotechnology. Clinical evidence illustrated that MAOB
inhibitors are recommended as monotherapy and added on therapy to levodopa. A large study
and further evidence are required in the field of future therapies to unwind the complexity of the
disease.
Publisher
Bentham Science Publishers Ltd.
Subject
Organic Chemistry,Computer Science Applications,Drug Discovery,General Medicine
Reference145 articles.
1. Obeso J.A.; Rodríguez-Oroz M.C.; Rodríguez M.; Lanciego J.L.; Artieda J.; Gonzalo N.; Olanow C.W.; Pathophysiology of the basal ganglia in Parkinson’s disease. Trends Neurosci 2000,23(10),S8-S19
2. Marvel C.L.; Paradiso S.; Cognitive and neurological impairment in mood disorders. Psychiatr Clin North Am [vii-viii.2004,27(1),19-36
3. Smith Y.; Wichmann T.; Factor S.A.; Delong M.R.; Parkinsons disease therapeutics: new developments and challenges since the introduction of levodopaNeuro psychopharmacol, 2011,37(1),213-246
4. Riederer P.; Müller T.; Monoamine oxidase-B inhibitors in the treatment of Parkinson’s disease: clinical-pharmacological aspects. J Neural Transm (Vienna) 2018,125(11),1751-1757
5. Carradori S.; Secci D.; Petzer J.P.; MAO inhibitors and their wider applications: a patent review. Expert Opin Ther Pat 2018,28(3),211-226
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献